AKT1 and breast cancer: miR-205 functions as tumor suppressor miRNA and improves the response to the TK inhibitors gefitinib (GEF) and LAP and to TRA through abrogating the expression of HER3 along with vascular endothelial growth factor A (VEGF-A) and targets AKT-mediated pathway in BC cells [133, 134].